Skip to content
Life Sciences Series B Founded 2012

RoosterBio

Developer of human mesenchymal stem cells and extracellular vesicles. The company specializes in human bone marrow-derived and adipose-derived MSCs and associated, highly-engineered media formulations for the expansion of these cells. Founded in 2012, headquartered in Frederick, United States. The company has raised $38.4M in funding at the series b stage. The team comprises 58 (Jun 30, 2026) employees. RoosterBio…

📍 Frederick, United States · Life Sciences Platforms and Tools,

Funding snapshot

Last roundSeries B
Amount$12M
Date8 March 2024
Total raised$38M
Team size58

About

Developer of human mesenchymal stem cells and extracellular vesicles. The company specializes in human bone marrow-derived and adipose-derived MSCs and associated, highly-engineered media formulations for the expansion of these cells. Founded in 2012, headquartered in Frederick, United States. The company has raised $38.4M in funding at the series b stage. The team comprises 58 (Jun 30, 2026) employees. RoosterBio operates in the Life Sciences Platforms and Tools, Cell Therapy, Genomics sectors. The company focuses on Bioreagents, Cell Culture. Notable investors include Maryland Stem Cell Research Fund, Vanedge Capital, Dynamk Capital, Planetary Technologies, HHS, TEDCO. The company has a team of 58 employees.

Business model

Genomics > Enabling Technologies > Kits and Reagents > Bioreagents,

Life Sciences Platforms and Tools > Research Reagents and Kits > Cell Culture

Institutional investors

Maryland Stem Cell Research Fund Vanedge Capital Dynamk Capital Planetary Technologies HHS TEDCO

Latest coverage

No articles yet.

Raising like RoosterBio?

Analyze your pitch deck before your next raise.

Analyze My Deck →